Latest News

29 November 2017

AGM Chairman’s address and CEO presentation

Chairman’s address and the CEO’s presentation to the 2017 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Read more

21 November 2017

NDA submission for Starpharma’s VivaGel® BV

BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage.

Go to article

21 November 2017

NDA submission for VivaGel® BV in the US

Melbourne, Australia: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that its US New Drug Application (NDA) submission for VivaGel® BV for both treatment and prevention of BV has been lodged with the FDA through a rolling submission process. 

Read more

27 October 2017

Notice of Annual General Meeting/Proxy Form

Download ASX Announcement: Notice of Annual General Meeting/Proxy Form (pdf, 643kb)… Read more

In the media

21 November 2017

NDA submission for Starpharma’s VivaGel® BV

BioSpectrum Asia reported on Starpharma’s NDA submission for VivaGel® BV, noting that Starpharma is one of the few Australian companies to take a locally developed product to this stage.

Go to article

25 October 2017

Starpharma receives TGA marketing approval for VivaGel® BV

Online financial news portal Finance News Network reported Starpharma received TGA marketing approval for VivaGel® BV, which is expected to be available in pharmacies in the new year under the Fleurstat™ brand.

Go to article

23 October 2017

Morgans Under the Microscope Interview featuring Dr Jackie Fairley

Morgans Under the Microscope series featured Starpharma's CEO, Dr Jackie Fairley, discussing a number of key milestones that are approaching and the licensing arrangements entered into with AstraZeneca. 

Listen to the podcast (external link). 

26 September 2017

Starpharma reports positive phase 1 results

Biotech news and industry publication Biotech Dispatch covered the news that Starpharma achieved positive results for its DEP® docetaxel phase 1 clinical trial and will transition immediately into phase 2.

Go to article (external link)

Shareholder Updates

18 October 2017

Shareholder Update October 2017

In this issue: 

>> DEP® docetaxel achieves positive phase 1 results and commences phase 2

 >> AZ presents first DEP® candidate AZD0466 – a Bcl2/xL inhibitor

>>  Successful VivaGel® BV phase 3 results

>> Update on other internal DEP® candidates

>> Grant awarded to Starpharma-Monash

>> Starpharma and Peter Mac Cancer Centre awarded grant

>> FY17 Financial results; >$60M cash at 30 June

>> Annual Report and Annual General Meeting

>> Starpharma News & Events

 

Download: Shareholder Update October 2017 (pdf file, 1.3mb)

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

Sign up to receive news here

© Starpharma Holdings Limited 2017